METiS Showcases First-in-Class Intravenous Muscle-Targeting LNP Platform at CRS 2024

Jul 08, 2024 17:31 CST Updated 17:31

METiS TechBio

AI-Driven Drug Formulation Developer

The 2024 Annual Meeting and Exposition of the Controlled Release Society (CRS 2024 Annual Meeting and Exposition) is being held in Bologna, Italy, from July 8th to 12th. The theme of this year's conference is "Integrating Delivery Science Across Disciplines."

The Controlled Release Society (CRS), established in 1978 and headquartered in St. Paul, Minnesota, USA, is a renowned international academic organization dedicated to the research of controlled release technologies. With branches established in over a dozen countries and regions globally, CRS has tens of thousands of members. Today, CRS has become the world's most authoritative non-profit academic organization in the field of Drug Delivery Systems (DDS), playing a significant role in promoting global academic exchange and industry development in DDS.

As a representative of a global leading "AI + Drug Delivery" company, METiS TechBio will present at the conference with "Using an AI- and ML-powered LNP Design Platform to Develop 4-Component LNPs for Muscle Cell Targeting via Intravenous Administration" as the title, shareLatest Research Achievements of First-in-Class Intravenous Administration Systemic Muscle-Targeted LNP, exploring the possibility of non-viral vector gene therapy for various systemic muscle atrophy conditions.

(METiS TechBio Speech Session)

Click

Read the Original Text

View More Details of the Conference

Learn More About METiS TechBio

"White Paper on Drug Delivery" Officially Released (with 112-page PDF download)

30 Academicians and the 38 Pharmaceutical Innovation Companies They Co-founded

The Innovation Rivalry of mRNA Delivery Under the Nobel Prize | Jianghu